Apellis Pharmaceuticals Inc (NASDAQ: APLS) is down nearly 40% versus its year-to-date high but a Mizuho analyst does not see it as an opportunity to buy per se. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins. Mizuho remains ‘neutral’ on Apellis Pharmaceuticals stock Copy link to section Graig Suvannavejh reiterated his “neutral” stance on the biotech stock in a recent research note. While his $52 price target does suggest meaningful upside from here ...